We are pleased to invite investors and analysts to participate in our virtual event on Tuesday, 8 December, 2020, highlighting Roche data presented at the virtual American Society of Hematology (ASH) 62nd Annual Meeting, from 5-8th December.
16:00 – 17:00 CET / 15:00 - 16:00 GMT
10:00 – 11:00 am EST / 7:00 – 8:00 am PST
The webinar will start with a presentation, followed by a Q&A session (live access to the speakers).
Agenda:
- Welcome
Karl Mahler, Head of Investor Relations and Roche Group Planning - Hematology Franchise Overview
Thomas Fuchs, Vice President, Hematology Franchise Head, Global Product Strategy - Review of Key Clinical Data Presented at ASH
Ginna Laport, Vice President & Global Head of Hematology NHL/CLL
Marion Ott, M.D., PhD - Global Franchise Head AML, Multiple Myeloma and Pediatric Development - Q&A
Access to virtual event (pre-registration required)
Please pre-register for our webinar here.*
A replay of the webcast will be available via ir.roche.com
| Best regards, | |
| Karl Mahler Head of Investor Relations and Roche Group Planning |
Loren Kalm Investor Relations Officer |
| Roche Investor Relations | |
| Dr. Karl Mahler Phone: +41 61 68-78503 e-mail: karl.mahler@roche.com |
Dr. Sabine Borngräber Phone: +41 61 68-88027 e-mail: sabine.borngraeber@roche.com |
| Dr. Bruno Eschli Phone: +41 61 68-75284 e-mail: bruno.eschli@roche.com |
Dr. Birgit Masjost Phone: +41 61 68-84814 e-mail: birgit.masjost@roche.com |
| Dr. Gerard Tobin Phone: +41 61 68-72942 e-mail: gerard.tobin@roche.com |
Jon Kaspar Bayard Phone: +41 61 68-83894 e-mail: jon_kaspar.bayard@roche.com |
| Investor Relations North America | |
| Loren Kalm Phone: +1 650 225 3217 e-mail: kalm.loren@gene.com |
Dr. Lisa Tuomi Phone: +1 650 467 8737 e-mail: tuomi.lisa@gene.com |
get the latest news and updates to your inbox.